Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which was thought to be untreatable. However, recent evidence in both experimental animals and men indicates that antiglutamatergic strategies are the first to have an influence on its pathogenesis and slow down the disease process. Since the effect of drugs is still small, this progress cannot only be seen as a success of the present but must also be acknowledged as a basis for future developments. How will future studies be designed? They will have to take into account that the disease presumably has a long preclinical period and they will use a number of novel compounds and treatment strategies which have been shown to be effective in transgenic animal models. This also implies that we are likely to use a combination of therapies and we will try to treat patients early. The latter will be associated with the demand for a novel clinical attitude toward the diagnosis of the disease and the development of novel markers for both the preclinical period and the longitudinal course of the disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF (2000) Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 47: 447–455
Andrews TC, Weeks RA, Turjanski N, Brooks DJ (1998) Monitoring disease progression in presymptomatic and early Huntington’s disease: D1 and D2 ligand PET and the unified Huntington’s rating scale. Neurology (suppl. 1) A 348
Andrus PK, Fleck TJ, Gurney ME, Hall ED (1998) Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041–2048
Antonini A, Leenders K, Eidelberg D (1998) (11C) Raclopride PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 43: 253–255
Azzouz M, Leclerc N, Gurney M, Warter J-M, Poindron P, Borg J (1997) Progressive motor neuron impairment in an animal model of familial amy-atrophic lateral sclerosis. Muscle Nerve 20: 45–51
Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. TINS 23: 298–304
Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585–591
Block W, Karitzky J, Traber F, Pohl C, Keller E, Mundegar RR, Lamerichs R, Rink H, Ries F, Schild HH, Jerusalem F. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease. Sub-group analysis and follow-up measurements. Arch Neurol, in press
Bogdanov MB, Ramos LE, Xu X, Beal MF (1998) Elevated “hydroxyl radical” generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 71: 1321–1324
Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327–338
Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild type SOD1. Science 281: 1851–1854
Charcot JM (1874) Lecons sur les maladies du systéme nerveux faites à la Salpetrière. Paris: Progrès Medical, pp 213–242
Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis TM, Gurney ME (1995) Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 6: 349–362
Dal Canto MC, Gurney ME (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 145: 1271–1279
Cummings JF, DeLaHunta A, George D, et al. (1990) Equine motor neuron disease: a preliminary report. Cornell Vet 80: 357–379
Dengler R, Konstanzer A, Küther G, Wolf W, Hesse S, Struppler A (1989) Collateral nerve sprouting and twitch forces of single motor units in conditions with partial denervation in man. Neurosci Lett 97: 118–122
Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47 (suppl 4) S233-S241
Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, et al. (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94: 9434–9439
Elitok E, Schmid M, Claus A, Karitzky J, Neumaier B, Tomczak R, Kotzerke J, Gerhard A, Landwehrmeyer B, Ludolph AC, Reske S N, Schwarz J, Tumani H (2000) 11c-pk11195 positron emission tomography (PET): An in vivo indicator for activated microglia in multiple sclerosis. lesions. J Neurol (Suppl. 3) 247: III/39
Ferrante RJ, Shinobu LA, Schulz JB, et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu, Zn superoxide dismutase mutation. Ann Neurol 42: 326–334
Friedländer RM, Brown RH, Gagliardini V, Wang J, Yuan J (1997) Inhibition of ICE slows ALS in mice. Science 388: 31
Gerhard A, Ludolph AC, Neumaier B, Tomczak R, Ries V, Elitok E, Reske SN, Schwarz J. In vivo imaging of activated microglia using (11c) Pk 11195 and positron emission tomography after ischemic stroke. Neuroreport, in press
Gerhard A, Schwarz J, Brookes D (2000) (11c) Pk 11195 microglia imaging ion patients suffering from multisystem atrophy. Movem Disord Suppl
Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hantati A, Kwon Y, Deng H, Chen W, Zhai P, Sifit R, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1773–1775
Gurney M, Cutting FB, Zhai P, Doble A, Taylor C, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157
Gurney ME, Fleck TJ, Himes CS, Hall ED (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50: 62–66
Hall E D, Oostveen JCA, Gurney ME (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23: 249–256
Hatazawa J, Brooks RA, Dalakas MC, et al. (1988) Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tom 12: 630–636
Hottinger AF, Fine EG, Gurney ME, Zurn AD, Aebischer P (1997) The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 9: 1548–1551
Ikonomidou C, Qin YQ, Labruyere J, Olney JW (1996) Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 55: 211–224
Klivenyi P, Ferrante RJ, Matthews RT, et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat Med 5: 347–350
Knirsch U, Sturm S, Reuter A, Bachus R, Gosztonyi G, Voelkel H, Ludolph AC (2000) Calcineurin and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice. Brain Res, in press
Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18: 3241–3250
Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S (1997) Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277: 559–562
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Doseranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431
Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288: 335–339
Liu R, Althaus JS, Ellerbrock BR, et al. (1998) Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 44: 763–770
Ludolph AC, Siddik M, Spencer PS (1991) Decline of ALS in the Irian Jaya disease epicenter. Neurology 41 (Suppl. 1) 259
Ludolph AC, Knirsch U (1999) Problems and pitfalls in the diagnosis of ALS. J Neurol Sci 165, S14-S20
Ludolph AC, Meyer T, Riepe MW (2000) The role of excitotoxicity in ALS: Which is the evidence? J Neurology 247: 7–16
Mazziotta JC, Phelps ME, Pahl JJ, et al. (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med 316: 357–362.
Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA (1996) The WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 47: 1383–1388
Morrish PK, Sawle GV, Brooks DJ (1996) An (18F) Dopa PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119: 585–591
Morrish PK, Sawle GV, Brooks DJ (1995) Clinical and (18F) Dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 59: 597–600
Nagano S, Ogawa Y, Yanagihara T, Sakoda S (1999) Benefit of a combined treatment with trienetine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 265: 159–162
Pioro EP, Majors AW, Mitsumoto H, Nelson DR, Ng TC (1999)1H-MRS evidence of neurodegeneration and excess glutamate+glutamine in ALS medulla. Neurology 53: 71–79.
Reaume AG, Elliott JL, Hoffman EK, et al. (1996) Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13: 43–47
Riepe M, Hori N, Ludolph AC, Carpenter DO, Spencer PS, Allen CA (1992) Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res 586: 61–66
Riepe HW, Hori N, Ludolph AC, Carpenter DO (1995) Failure of neuronal ion exchange, not potentiated excitation causes excitotoxicity after inhibition of oxidative phosphorylation. Neuroscience 64: 91–97
Riviere M, Meininger V, Zeisser P, Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55: 526–528
Rosen DR, Siddique T, Patterson D, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62
Sehrsam I, Ludolph: AC Unpublished work
Shoulson I (1998) Experimental therapeutics for neurodegenerative disorders: unmet needs. Science 282: 1072–1074
Spencer PS, Allen CN, Kisby GE, Ludolph AC, Ross SM, Roy DN (1991) Lathyrism and western Pacific amyotrophic lateral sclerosis: etiology of short and long, latency motor-system disorders. In: Rowland LP (ed) Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Advances in Neurology. Vol. 56. Raven Press, New York, pp 287–300
Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105–1116
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ludolph, A.C. Treatment of amyotrophic lateral sclerosis— What is the next step?. J Neurol 247 (Suppl 6), 13–18 (2000). https://doi.org/10.1007/BF03161074
Issue Date:
DOI: https://doi.org/10.1007/BF03161074